InnoCan PharmaHAM:IP40 +6.19%62 Forward Dividend Yield % is 0.00% as of Jun. 29, 2026. GuruFocus rates HAM:IP40 with a GF Score™ of 62/100 and a GF Value™ of €9.62 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,159 Consumer Packaged Goods companies, InnoCan Pharma ranks worse than 86281.19% on this metric.
As of today (2026-06-29), the Forward Annual Dividend Yield of InnoCan Pharma is 0.00%.
As of today (2026-06-29), the Trailing Annual Dividend Yield of InnoCan Pharma is 0.00%.
HAM:IP40's Forward Dividend Yield % is not ranked *
in the Consumer Packaged Goods industry.
Industry Median: 3.11 * Ranked among companies with meaningful Forward Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
InnoCan Pharma Forward Dividend Yield % Related Terms
HAM:IP40 vs PG, CL, KVUE: Forward Dividend Yield % Comparison
For the Household & Personal Products subindustry, InnoCan Pharma's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InnoCan Pharma Forward Dividend Yield % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, InnoCan Pharma's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where InnoCan Pharma's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
InnoCan Pharma (HAM:IP40) has a Forward Dividend Yield % of 0.00% as of Jun. 29, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on InnoCan Pharma and its competitors. According to the industry distribution chart, InnoCan Pharma ranks #999999 out of 1159 companies in the Consumer Packaged Goods industry.
Is InnoCan Pharma's Forward Dividend Yield % too high?
InnoCan Pharma's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, InnoCan Pharma ranks #999999 out of 1159 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, InnoCan Pharma has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCan Pharma's Forward Dividend Yield % compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, InnoCan Pharma ranks #999999 out of 1159 companies for Forward Dividend Yield %. This places InnoCan Pharma in the lower half of its industry. The industry median Forward Dividend Yield % is 3.11. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Consumer Packaged Goods company?
The median Forward Dividend Yield % among Consumer Packaged Goods companies is 3.11, based on 1,159 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on InnoCan Pharma and its competitors. For the Consumer Packaged Goods industry, the median Forward Dividend Yield % is 3.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InnoCan Pharma's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCan Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCan Pharma (HAM:IP40) is currently considered Possible Value Trap. The stock's GF Value™ is €9.62, compared to a current price of €1.63 — trading 83.1% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. InnoCan Pharma's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For InnoCan Pharma (HAM:IP40), the current Forward Dividend Yield % is 0.00% as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InnoCan Pharma (HAM:IP40) Overvalued in 2026?
Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued.
The current stock price of €1.63 is trading 83.1% below its estimated GF Value™ of €9.62.
GuruFocus considers InnoCan Pharma to be Possible Value Trap.
Key valuation signals for HAM:IP40:
Forward Dividend Yield %: 0.00%
GF Value™: €9.62 vs. price of €1.63 (83.1% below fair value)
No single metric tells the full story. See the HAM:IP40 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
62GF Score
Get the complete analysis for HAM:IP40
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:IP40 has been successfully added to your 